Bayer's Landmark Settlement Faces Delay as Plaintiffs Push Back

Plaintiff lawyers seek a 60-day delay in court review of Bayer's glyphosate deal, creating new uncertainty ahead of the company's key earnings report on March 4.

A critical deadline in Bayer AG's multi-billion dollar glyphosate settlement is now under threat. Legal representatives for nearly 20,000 plaintiffs are actively opposing the company's proposed timeline, calling for a postponement of the court's review by a minimum of 60 days. This fresh layer of uncertainty arrives at an inconvenient moment for the pharmaceutical and agrochemical giant, with its annual financial results scheduled for release on March 4.

Legal Teams Challenge Accelerated Court Review

The dispute centers on whether the intricate settlement package should receive preliminary court approval as early as March 4. This date falls just two weeks after the terms were publicly disclosed in mid-February. Attorneys for the claimants argue this schedule is impractical, stating their clients—cancer patients and their families—require substantially more time to properly evaluate the settlement's extensive conditions.

Bayer has defended its proposal as equitable and continues to press for a swift resolution. The company is eager to finally close the chapter on U.S. litigation surrounding its glyphosate-based Roundup product. However, a specific clause within the agreement introduces a significant risk: Bayer retains the right to withdraw from the deal if an insufficient number of plaintiffs opt to participate. Any delay in the process could potentially undermine the crucial participant acceptance rate the company needs.

Earnings Report Overshadowed by Legal Uncertainties

These legal complications cast a shadow over a pivotal week for investors. On March 4, the group is set to publish its fourth-quarter and full-year 2025 results. Market participants will be scrutinizing not only the financial figures but also management's guidance for 2026 and its assessment of the ongoing legal challenges in the United States. The share price, currently trading at €41.75, remains well below the 52-week high of €49.17 it reached in February, reflecting the persistent market concerns.